Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bicara Therapeutics Inc. (BCAX)
NASDAQ:BCAX
RESEARCH TOOLSreports
Holding BCAX?
Track your performance easily
BCAX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$16.01 - $28.09
Previous Close$17.59
Volume4.29M
Average Volume (3M)415.67K
Market Cap
$957.17M
Enterprise Value$753.62M
Total Cash (Recent Filing)$203.85M
Total Debt (Recent Filing)$300.00K
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Nov 12, 2024EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,415,619
10 Day Avg. Volume464,257
30 Day Avg. Volume415,671
Standard Deviation0.04
R-Squared1.00
Alpha-0.08
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$43.25Price Target Upside145.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bicara Therapeutics Inc. News
PremiumCompany Announcements
Bicara Therapeutics Reports Strong IPO and Clinical Advancements
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressBCAX's lead asset, ficerafusp alfa, has shown impressive efficacy in combination with pembrolizumab relative to standard-of-care among HPV-negative 1L R/M HNSCC patients in a Ph1/1b study.
Market Potential And ValuationBicara trades at a significant valuation discount compared to its key competitor, offering potential value for investors.
Therapeutic AdvancementsBicara Therapeutics is developing a bifunctional antibody that targets two validated cancer drug development targets, potentially offering superior efficacy and safety in cancer treatment.
Bears Say
Clinical Trial RisksRisks include potential negative clinical results with ficerafusp alfa and delays in advancing it into registrational trials.
Competitive LandscapeThere are competitive landscape risks, especially concerning other bispecifics currently in clinical development.
Competitor AdvancementsCompetitor MRUS recently entered Ph3 development in 1L R/M HNSCC with its dual-targeting antibody petosemtamab, which has shown comparable response rates in patients.
---
Ownership Overview
37.38% Insiders
1.69% Mutual Funds
49.02% Other Institutional Investors
11.74% Public Companies and
Individual Investors
BCAX FAQ
What was Bicara Therapeutics Inc.’s price range in the past 12 months?
Bicara Therapeutics Inc. lowest stock price was $16.01 and its highest was $28.09 in the past 12 months.
What is Bicara Therapeutics Inc.’s market cap?
Currently, no data Available
When is Bicara Therapeutics Inc.’s upcoming earnings report date?
Bicara Therapeutics Inc.’s upcoming earnings report date is Nov 12, 2024 which is 41 days ago.
How were Bicara Therapeutics Inc.’s earnings last quarter?
Currently, no data Available
Is Bicara Therapeutics Inc. overvalued?
According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued.
Does Bicara Therapeutics Inc. pay dividends?
Bicara Therapeutics Inc. does not currently pay dividends.
What is Bicara Therapeutics Inc.’s EPS estimate?
Bicara Therapeutics Inc.’s EPS estimate is -$0.41.
How many shares outstanding does Bicara Therapeutics Inc. have?
Bicara Therapeutics Inc. has 54,415,620 shares outstanding.
What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?
Currently, no hedge funds are holding shares in BCAX
---
Bicara Therapeutics Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Company Description
Bicara Therapeutics Inc.
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, or HNSCC, where there remains a significant unmet need. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic HNSCC excluding HPV-positive patients with oropharyngeal squamous cell carcinoma late in the fourth quarter of 2024 or early in the first quarter of 2025.
---
BCAX Stock 12 Month Forecast
Average Price Target
$43.25
▲(145.88% Upside)
Technical Analysis
Best Analysts Covering BCAX
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-19.53%
assigned a buy rating 14 days ago
Copying Judah Frommer's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -19.53% per trade.
---